在韩国,用于治疗骨质疏松症的连续denosumab治疗的成本后果分析
Seungju Cha1, Minjeong Sohn2, Hyowon Yang2
1NDnex, Saebitgongwon-ro 67, Gwangmyeong-si, Gyeonggi-do, 14348, Republic of Korea.
BMC musculoskeletal disorders
|January 20, 2024
概括
在T评分>2.0之前的连续denosumab治疗 (Dmab-C) 预防了更多的骨折和死亡,而不是在T评分>-2.5.5时停止治疗 (Dmab-D). 对于骨质疏松症患者来说,Dmab-C提供了显著的长期医疗成本节省.
科学领域:
- 药物经济学 药物经济学
- 骨质疏松症管理管理
- 卫生经济学 卫生经济学
背景情况:
- 韩国的保险限制了对T-score>-2.5.5的骨质疏松症药物的使用.
- 这项研究比较了连续使用的德诺苏马布 (Dmab-C) 的T-score>-2.0与在T-score>-2.5.5中停止使用 (Dmab-D) 的情况.
研究的目的:
- 评估Dmab-C与Dmab-D的财务影响.
- 与Dmab-D相比,评估Dmab-C的骨折预防疗效.
- 确定韩国骨质疏松症患者的最佳denosumab治疗策略.
主要方法:
- 从韩国医疗保健系统的角度进行成本后果分析.
- 利用新开发的马尔科夫模型进行终身模拟.
- 估计脊椎和非脊椎骨折的发生率,与骨折相关的死亡和相关成本.
主要成果:
- 在一生中,每100名患者中,Dmab-C策略预防了32.21例脊椎骨折和12.43例非脊椎骨折.
- 在每100名患者中,Dmab-C可减少1.29个骨折相关死亡.
- 终身医疗费用节省了每位患有Dmab-C的患者1,354,655韩元,当包括生产力损失在内时,增加到29,025,949韩元.
结论:
- 直到T评分>2.0为止的连续denosumab治疗提供了卓越的临床和经济效益.
- 这一策略显著提高了骨折的预防和降低死亡风险.
- 实施Dmab-C可以降低骨质疏松症管理中的整体医疗费用.
更多相关视频
相关概念视频
01:40Bone Remodeling
38.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.3K
01:31Osteoclasts in Bone Remodeling
2.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K
01:29Bone Disorders
3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K